Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We investigated the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer and sought associations between the mutation status of the KRAS gene in tumors and clinical response to cetuximab. METHODS: We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab. The primary end point was progression-free survival. RESULTS: A total of 599 patients received cetuximab plus FOLFIRI, and 599 received FOLFIRI alone. The hazard ratio for progression-free survival in the cetuximab-FOLFIRI group as compared with the FOLFIRI group was 0.85 (95% confidence interval [CI], 0.72 to 0.99; P=0.048). There was no significant difference in the overall survival between the two treatment groups (hazard ratio, 0.93; 95% CI, 0.81 to 1.07; P=0.31). There was a significant interaction between treatment group and KRAS mutation status for tumor response (P=0.03) but not for progression-free survival (P=0.07) or overall survival (P=0.44). The hazard ratio for progression-free survival among patients with wild-type-KRAS tumors was 0.68 (95% CI, 0.50 to 0.94), in favor of the cetuximab-FOLFIRI group. The following grade 3 or 4 adverse events were more frequent with cetuximab plus FOLFIRI than with FOLFIRI alone: skin reactions (which were grade 3 only) (in 19.7% vs. 0.2% of patients, P<0.001), infusion-related reactions (in 2.5% vs. 0%, P<0.001), and diarrhea (in 15.7% vs. 10.5%, P=0.008). CONCLUSIONS: First-line treatment with cetuximab plus FOLFIRI, as compared with FOLFIRI alone, reduced the risk of progression of metastatic colorectal cancer. The benefit of cetuximab was limited to patients with KRAS wild-type tumors. (ClinicalTrials.gov number, NCT00154102.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Sub-analysis revealed that the benefits of cetuximab were limited to patients with KRAS wild-type (wt) tumors.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [16]
In the citing paper
“The results of this trial demonstrated a decrease in progression-free survival but no difference in overall survival.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [16]
In the citing paper
“Some large clinical trials have shown that FOLFIRI (leucovorin + 5-FU + irinotecan) or FOLFOX regimens combined with EGFR inhibitors can benefit KRAS-WT CRC.”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [150]
In the citing paper
“However, CRC with KRAS mutations do not benefit from EGFR inhibitors, possibly because activation of KRAS does not depend upstream on EGFR [149,150,151,152].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [150]
In the citing paper
“According to the CRYSTAL trial, the application of cetuximab and FOLFIRI in first-line treatment can reduce the risk of progression by 15% and increase overall survival (OS) by 8.2 months in patients who have KRAS WT mCRC compared with patients taking FOLFIRI alone [5].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [5]
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Statistical Methods for Rates and Proportions, 2nd ed
GROVE, W. A. (1981) · American Journal of Psychiatry · doi:10.1176/ajp.138.12.1644-a · Cited by 3,748
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Self-citationWild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Research works printed but not linked: 3
- Rougier P, 2004, J Clin Oncol, 22, 248s, 10.1200/jco.2004.22.14_suppl.3513 · doi:10.1200/jco.2004.22.14_suppl.3513
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Schilsky RL, 2002, Clin Cancer Res, 8, 935
Cited by
Items 501–600 of 1,017
Zaanan, A., Gauthier, M., Malka, D., Locher, C., Gornet, J., Thirot‐Bidault, A., Tougeron, D., Taïeb, J., Bonnetain, F., & Aparicio, T. (2010) · Cancer · doi:10.1002/cncr.25614 · Cited by 90
“Targeted therapies such as monoclonal antibodies against vascular endothelial growth factor (VEGF) or epidermal growth factor receptor (EGFR) combined with chemotherapy have already shown significant efficacy in metastatic CRC in first-line treatment and beyond.23-26 Overman et al observed that a high proportion of SB…”
BackgroundStintzing, S., Kapaun, C., Laubender, R. P., Jung, A., Neumann, J. H. L., Modest, D. P., Giessen, C. A., Moosmann, N., Wollenberg, A., Kirchner, T., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27654 · Cited by 90
“Meanwhile, it has become increasingly clear that KRAS mutational status is not the only determinant of cetuximab-related treatment efficacy because even in patients with KRAS wild-type tumours response is not achieved in about 40%.(1,2) Furthermore, there is evidence to suggest that KRAS codon-13-mutated tumours might…”
Ayez, N., van der Stok, E. P., Grünhagen, D. J., Rothbarth, J., van Meerten, E., Eggermont, A. M. M., & Verhoef, C. K. (2015) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2015.04.012 · Cited by 89
Assénat, E., Desseigne, F., Thézenas, S., Viret, F., Mineur, L., Kramar, A., Samalin, E., Portales, F., Bibeau, F., Crapez-Lopez, E., et al. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0141 · Cited by 91
“9% seems to be interesting, compared with previous results with cetuximab plus doublet chemotherapy [13–18] or FOLFIRINOX alone [7, 9, 10].”
BackgroundResultAdackapara, C., Sholl, L. M., Barletta, J. A., & Hornick, J. L. (2013) · Histopathology · doi:10.1111/his.12154 · Cited by 86
“Approximately 25% of patients present with metastases, which portend a 5-year survival rate of <10%.(29) The median survival for patients with metastatic CRC has improved in the last 10 years from 10 months to >20 months with the development of new chemotherapeutic agents, and agents targeting EGFR and VEGF.”
BackgroundPillay, V., Gan, H. K., & Scott, A. M. (2011) · New Biotechnology · doi:10.1016/j.nbt.2011.03.021 · Cited by 91
Paz-Ares, L. G., Gomez-Roca, C., Delord, J.-P., Cervantes, A., Markman, B., Corral, J., Soria, J.-C., Bergé, Y., Roda, D., Russell-Yarde, F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.8888 · Cited by 80
Cutsem, E. V., Dicato, M. A., Arber, N., Berlin, J. D., Cervantes, A. M. R., Ciardiello, F., de Gramont, A., Díaz‐Rubio, E., Ducreux, M. P., Geva, R., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq273 · Cited by 87
Self-citationTol, J., Dijkstra, J. R., Vink-Börger, M. E., Nagtegaal, I. D., Punt, C. J. A., van Krieken, J. H., & Ligtenberg, M. J. L. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00788.x · Cited by 91
“Clinical studies already use a real-time PCR-based assay [6, 10, 13] but the assay has not been directly compared with sequencing.”
MethodRoukos, D. H., Katsios, C. G., & Liakakos, T. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.49 · Cited by 81
Using Genome Sequence to Enable the Design of Medicines and Chemical Probes
Angelbello, A. J., Chen, J. L., Childs‐Disney, J. L., Zhang, P., Wang, Z.-F., & Disney, M. D. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00504 · Cited by 81
China CRLM Guideline Group, Xu, J., Fan, J., Qin, X., Cai, J., Gu, J. F., Wang, S., Wang, X., Zhang, S., & Zhang, Z. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2795-1 · Cited by 83
ADAM17: An Emerging Therapeutic Target for Lung Cancer
Saad, M. I., Rose‐John, S., & Jenkins, B. J. (2019) · Cancers · doi:10.3390/cancers11091218 · Cited by 89
Molecular Network of Colorectal Cancer and Current Therapeutic Options
Huang, Z., & Yang, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.852927 · Cited by 96
“2 months compared with patients treated with FOLFIRI alone in the CRYSTAL study (114, 115).”
MethodPander, J., Gelderblom, H. A. J., Antonini, N. F., Tol, J., van Krieken, J. H., van der Straaten, T., Punt, C. J. A., & Guchelaar, H. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.03.017 · Cited by 88
Köhne, C., Hofheinz, R., Mineur, L., Letocha, H., Greil, R., Thaler, J., Fernebro, E., Gamelin, E. C., DeCosta, L., & Karthaus, M. (2011) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-011-1061-6 · Cited by 83
Self-citationTargeted Therapies for Non–Small Cell Lung Cancer: An Evolving Landscape
Pal, S. K., Figlin, R. A., & Reckamp, K. L. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0239 · Cited by 93
“Given its established role in colorectal cancer, KRAS mutational status has been assessed in NSCLC patients receiving cetuximab (69).”
BackgroundTargeted therapies in colorectal cancer—an integrative view by PPPM
Hagan, S., Orr, M. C. M., & Doyle, B. J. (2013) · The EPMA Journal · doi:10.1186/1878-5085-4-3 · Cited by 106
Cell-surface proteomics for the identification of novel therapeutic targets in cancer
Kuhlmann, L., Cummins, E., Samudio, I., & Kislinger, T. (2018) · Expert Review of Proteomics · doi:10.1080/14789450.2018.1429924 · Cited by 81
Yoo, D. S., Kirkpatrick, J. P., Craciunescu, O. I., Broadwater, G., Peterson, B. L., Carroll, M. D., Clough, R. W., MacFall, J. R., Hoang, J. K., Scher, R. L., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1982 · Cited by 81
Hamblin, A. D., Wordsworth, S., Fermont, J. M., Page, S., Kaur, K., Camps, C., Kaisaki, P. J., Gupta, A., Talbot, D. C., Middleton, M. R., et al. (2017) · PLoS Medicine · doi:10.1371/journal.pmed.1002230 · Cited by 90
Peeters, M., & Price, T. J. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.08.002 · Cited by 86
Evidence for treatment strategies in sinonasal adenocarcinoma
Lund, V. J., Chisholm, E. J., Takes, R. P., Suarez, C. M., Mendenhall, W. M., Rinaldo, A., Llorente, J. L., Terhaard, C. H. J., Rodrigo, J. P., Maughan, E. F., et al. (2011) · Head & Neck · doi:10.1002/hed.21770 · Cited by 80
Carden, C. P., Sarker, D., Postel-Vinay, S. C., Yap, T. A., Attard, G., Banerji, U., Garrett, M. D., THOMAS, G. V., Workman, P., Kaye, S. B., et al. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.11.006 · Cited by 88
“69, 565–572 86 Van Beuningen, R. et al. (2006) Use of flow-through peptide-microarrays for cell- lysate profiling.”
MethodInfluentialKao, H.-W., Lin, Y.-Y., Chen, C., Chi, K., Tien, D., Hsia, C.-C., Lin, M.-H., & Wang, H. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.04.002 · Cited by 79
Palliative care and end-stage colorectal cancer management: The surgeon meets the oncologist
Costi, R., Leonardi, F., Zanoni, D., Violi, V., & Roncoroni, L. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i24.7602 · Cited by 90
Genotypes Affecting the Pharmacokinetics of Anticancer Drugs
den Besten-Bertholee, D., Maring, J. G., & Kuilenburg, A. B. P. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0450-z · Cited by 88
Liver transplantation for unresectable colorectal liver metastases: A systematic review
Moris, D., Tsilimigras, D. I., Chakedis, J. M., Beal, E. W., Felekouras, E. S., Vernadakis, S., Schizas, D., Fung, J. J., & Pawlik, T. M. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24671 · Cited by 79
Comparative Assessment of Protein Kinase Inhibitors in Public Databases and in PKIDB
Bournez, C., Carles, F., Peyrat, G., Aci‐Sèche, S., Bourg, S., Meyer, C., & Bonnet, P. (2020) · Molecules · doi:10.3390/molecules25143226 · Cited by 83
Tan, D. S. W., Gerlinger, M., Teh, B. T., & Swanton, C. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.03.019 · Cited by 85
Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer
Jehn, C., Böning, L., Kröning, H., Possinger, K., & Lüftner, D. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.554 · Cited by 79
Cleary, J. M., Tanabe, K., Lauwers, G. Y., & Zhu, A. X. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0152 · Cited by 83
“Remarkably, the Cetuximab Combined with Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer (CRYSTAL) study demonstrated that the response rate for FOLFIRI plus cetuximab was 59% in patients with K-Ras wild-type tumors [ 61 ].”
BackgroundRadiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy
Sihver, W., Pietzsch, J., Krause, M., Baumann, M. A., Steinbach, J., & Pietzsch, H. (2014) · Pharmaceuticals · doi:10.3390/ph7030311 · Cited by 78
“There are several studies about treatment of, particularly, head and neck cancer or colorectal cancer with cetuximab combined with chemotherapy, that show prolonged median overall survival [27–29],”
BackgroundReduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer
Yan, P., Klingbiel, D., Saridaki, Z., Ceppa, P., Curto, M., McKee, T. A., Roth, A., Tejpar, S., Delorenzi, M., Bosman, F. T., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0939 · Cited by 78
Self-citationQu, X., Sandmann, T., Frierson, H. F., Fu, L., Fuentes, E., Walter, K., Okrah, K., Rumpel, C. A., Moskaluk, C. A., Lu, S., et al. (2016) · Oncogene · doi:10.1038/onc.2016.170 · Cited by 78
De Robertis, M., Loiacono, L., Fusilli, C., Poeta, M. L., Mazza, T., Sanchez, M., Marchionni, L., Signori, E., Lamorte, G., Vescovi, A. L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0709 · Cited by 78
“It is known, indeed, that even in patients with WT KRAS, the efficacy of cetuximab therapy is restricted to a small subset of patients and is not sustainable (52).”
BackgroundBertorelle, R., Briarava, M., Rampazzo, E., Biasini, L., Agostini, M., Maretto, I., Lonardi, S., Friso, M. L., Mescoli, C., Zagonel, V, et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.602 · Cited by 77
“Although a predictive value of KRAS mutation status for response to EGFR-targeted therapy has been defined (Van Cutsem et al, 2009; Cunningham et al, 2010), its prognostic value is still unclear (Menin et al, 2006; Kim et al, 2007; Cunningham et al, 2010).”
BackgroundSmarter drugs emerging in pancreatic cancer therapy
Kleger, A., Perkhofer, L., & Seufferlein, T. T. W. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu013 · Cited by 83
“However, it remains to be defined whether these associations are prognostic or predictive [25–28].”
BackgroundZhou, G., Noordam, L., Sprengers, D., Doukas, M., Boor, P. P. C., van Beek, A. A., Erkens, R. G. A., Mancham, S., Grünhagen, D. J., Menon, A. G., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1448332 · Cited by 84
“Patients with unresectable LM-CRC have a poor prognosis with a median survival of only two years.(11) Therefore, there is a pressing need for more effective therapeutic strategies for”
BackgroundKawakami, H., Okamoto, I., Yonesaka, K., Okamoto, K., Shibata, K., Shinkai, Y., Sakamoto, H., Kitano, M., Tamura, T., Nishio, K., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2663 · Cited by 78
“Well-established causes of de novo resistance to cetuximab include activating mutations in codon 12 or 13 of KRAS and in BRAF [1–4].”
Correale, P., Botta, C., Cusi, M. G., Vecchio, M. T. D., Santi, M. M. D., Savellini, G. G., Bestoso, E., Apollinari, S., Mannucci, S., Marra, M., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26181 · Cited by 89
Overview of Systemic Therapy for Colorectal Cancer
Goodwin, R. A., & Asmis, T. R. (2009) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0029-1242465 · Cited by 86
“94).(18) OVERVIEW OF SYSTEMIC THERAPY FOR COLORECTAL CANCER/GOODWIN, ASMIS 253”
BackgroundYoshino, T., Hasegawa, Y., Takahashi, S., Monden, N., Homma, A., Okami, K., Onozawa, Y., Fujii, M., Taguchi, T., de Blas, B., et al. (2013) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyt034 · Cited by 77
“In colorectal cancer, the benefits of cetuximab are restricted to patients with KRAS wt tumors (21,22).”
BackgroundDienstmann, R., Patnaik, A., Garcia-Carbonero, R., Cervantes, A., Benavent, M., Roselló, S., Tops, B. B. J., van der Post, R. S., Argilés, G., Skartved, N. J. Ø., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1432 · Cited by 77
Fakih, M., & Wong, R. (2010) · Current Oncology · doi:10.3747/co.v17is1.616 · Cited by 76
The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance
Sickmier, E. A., Kurzeja, R. J. M., Michelsen, K., Vazir, M., Yang, E., & Tasker, A. S. (2016) · PLOS ONE · doi:10.1371/journal.pone.0163366 · Cited by 76
Right- and left-sided colorectal cancers respond differently to cetuximab
Wang, F., Bai, L., Liu, T.-S., Yu, Y.-Y., He, M.-M., Liu, K.-Y., Luo, H.-Y., Zhang, D.-S., Jin, Y., Wang, F.-H., et al. (2015) · Chinese Journal of Cancer · doi:10.1186/s40880-015-0022-x · Cited by 75
Johnsson, A., Hagman, H., Frödin, J., Berglund, Å., Keldsen, N., Fernebro, E., Sundberg, J., Christensen, R. D., Spindler, K.-L. G., Bergström, D., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt236 · Cited by 77
Cetuximab-conjugated iron oxide nanoparticles for cancer imaging and therapy
Chu, I., Tseng, S., & Chou, M. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s80134 · Cited by 82
“The US Food and Drug Administration has approved cetuximab as first-line treatment for K-ras wild-type EGFR-expressing metastatic colorectal cancer in combination with FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin).(6,7) Cetuximab is also indicated for the treatment of locally advanced squamous cell carcinoma of…”
BackgroundManagement of colon cancer: resource-stratified guidelines from the Asian Oncology Summit 2012
Ku, G. Y., Tan, I. B., Yau, T. C. C., Boku, N., Laohavinij, S., Cheng, A., Kang, Y., & Lopes, G. D. L., Jr. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70424-2 · Cited by 79
Schou, J. V., Rossi, S., Jensen, B. V., Nielsen, D. L., Pfeiffer, P., Høgdall, E. V. S., Yilmaz, M., Tejpar, S., Delorenzi, M., Kruhøffer, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099886 · Cited by 84
“Besides being significant for OS in the entire cohort, miR-345 was statistically significant in all survival models for subgroups of patients with wt of KRAS, BRAF, PI3KCA and double wt for the combinations, KRAS+BRAF and KRAS+PI3KCA, see Tables S2–6 in file S1. miR-345 was prognostic for OS in the BRAF+PI3KCA wt grou…”
BackgroundInfluentialSelf-citationTrotta, A. M., Ottaiano, A., Romano, C., Nasti, G., Nappi, A. G., Divitiis, C. D., Napolitano, M., Zanotta, S., Casaretti, R., D’Alterio, C., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0184 · Cited by 86
Trial Watch: Adoptively transferred cells for anticancer immunotherapy
Fournier, C., Martin, F., Zitvogel, L., Kroemer, G., Galluzzi, L., & Apétoh, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1363139 · Cited by 82
Lindauer, M., & Hochhaus, A. (2014) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-54490-3_2 · Cited by 91
MacKay, H. J., Eisenhauer, E. A., Kamel‐Reid, S., Tsao, M., Clarke, B. A., Karakasis, K., Werner, H. M. J., Trovik, J., Akslen, L. A., Salvesen, H. B., et al. (2013) · Cancer · doi:10.1002/cncr.28414 · Cited by 78
The emerging role of immunotherapy in colorectal cancer
Lynch, D. H., & Murphy, A. G. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.08.29 · Cited by 76
“Abs which have been approved include: cetuximab (63) or panitumumab (64) which targets EGFR and anti-VEGF Abs bevacizumab (65) and aflibercept (66).”
BackgroundTherapeutic strategy in unresectable metastatic colorectal cancer: an updated review
Chibaudel, B., Tournigand, C., Bonnetain, F., Richa, H., Benetkiewicz, M., André, T., & de Gramont, A. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015572343 · Cited by 80
Growth pattern of colorectal liver metastasis as a marker of recurrence risk
Eefsen, R. L., Vermeulen, P. B., Christensen, I. J., Lærum, O. D., Mogensen, M. B., Rolff, H. C., den Eynden, G. G. V., Høyer‐Hansen, G., Østerlind, K., Vainer, B., et al. (2015) · Clinical & Experimental Metastasis · doi:10.1007/s10585-015-9715-4 · Cited by 84
Guren, T. K., Thomsen, M., Kure, E. H., Sorbye, H., Glimelius, B., Pfeiffer, P., Österlund, P., Sigurdsson, F., Lothe, I. M. B., Dalsgaard, A. M., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.93 · Cited by 74
“In view of the results of NORDIC-VII, together with the data from COIN and the New EPOC trials (Maughan et al, 2011; Primrose et al, 2014), as compared to trials where cetuximab was combined with irinotecan-based regimens (Van Cutsem et al, 2009), it may be discussed whether cetuximab and oxaliplatin are good partners.”
InfluentialEGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases
Vaishnavi, A., Schubert, L., Rix, U., Marek, L. A., Le, A. T., Keysar, S. B., Glogowska, M. J., Smith, M. A., Kako, S. L., Sumi, N. J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0109 · Cited by 78
“Wild-type EGFR is an established therapeutic target in HNSCC, colorectal cancer, and squamous cell lung cancer and thus plays an important role in cancer cell signaling in these tumors (21-23).”
Tao, Y., Auperin, A., Sire, C., Martin, L., Khoury, C., Maingon, P., Bardet, É., Kaminsky, M., Lapeyre, M., Chatellier, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.2518 · Cited by 81
Systems Medicine: A Real Approach for Future Personalized Oncology?
Roukos, D. H. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.36 · Cited by 76
Bahrami, A., Hassanian, S. M., Shahidsales, S., Farjami, Z., Hasanzadeh, M., Anvari, K., Aledavood, A., Maftouh, M., Ferns, G. A., Khazaei, M., et al. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25890 · Cited by 78
“There was a small improvement in progression-free survival (PFS) with the combination therapy (Van Cutsem et al., 2009).”
BackgroundInoue, Y., Iwata, T., Okugawa, Y., Kawamoto, A., Hiro, J., Toiyama, Y., Tanaka, K., Uchida, K., Mohri, Y., Miki, C., et al. (2012) · Oncology · doi:10.1159/000343822 · Cited by 77
Sundström, M., Edlund, K., Lindell, M., Glimelius, B., Birgisson, H., Micke, P., & Botling, J. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-660 · Cited by 74
Scartozzi, M., Mandolesi, A., Giampieri, R., Pierantoni, C., Loupakis, F., Zaniboni, A., Galizia, E., Giustini, L., Silva, R. R., Bisonni, R., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25193 · Cited by 74
Guo, G.-F. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i43.4779 · Cited by 74
Karanicolas, P. J., Metrakos, P. P., Chan, K., Asmis, T. R., CHEN, E., Kingham, T. P., Kemeny, N. E., Porter, G. A., Fields, R. C., Pingpank, J., et al. (2013) · Current Oncology · doi:10.3747/co.21.1577 · Cited by 77
Ciombor, K. K., & Bekaii‐Saab, T. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0203 · Cited by 78
Yang, Z., Wu, X., Huang, Y., Di, M., Zheng, D., Chen, J., Ding, H., Mao, C., & Tang, J.-L. (2013) · International Journal of Cancer · doi:10.1002/ijc.28153 · Cited by 82
Wang, J., Chen, B., Wang, Y., Tsai, Y.-T., Chen, W.-C., Chang, W., Hou, M., Wu, Y., & Chang, W.-C. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.08.017 · Cited by 75
Biomarker-Based Prediction of Response to Therapy for Colorectal Cancer
Ross, J. S., Torres‐Mora, J., Wagle, N., Jennings, T. A., & Jones, D. (2010) · American Journal of Clinical Pathology · doi:10.1309/ajcp2y8ktdpoaorh · Cited by 79
Abrahão, A. B. K., Ko, Y., Berry, S. R., & Chan, K. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.10.016 · Cited by 74
Liu, Y., Starr, M. D., Bulusu, A., Pang, H., Wong, N. S., Honeycutt, W., Amara, A., Hurwitz, H. I., & Nixon, A. B. (2013) · Cancer Medicine · doi:10.1002/cam4.71 · Cited by 73
“First-line chemotherapy has been shown to improve clinical outcomes, with the median overall survival (OS) of patients with metastatic CRC now approaching 20–24 months [2–4].”
BackgroundLiver Resection for Colorectal Cancer Metastases
Gallinger, S., Biagi, J. J., Fletcher, G. G., Nhan, C., Ruo, L., & McLeod, R. S. (2013) · Current Oncology · doi:10.3747/co.20.1341 · Cited by 76
Novel Therapies to Inhibit Mucus Synthesis and Secretion in Airway Hypersecretory Diseases
Ha, E. V. S., & Rogers, D. F. (2015) · Pharmacology · doi:10.1159/000442794 · Cited by 77
Scartozzi, M., Bearzi, I., Mandolesi, A., Pierantoni, C., Loupakis, F., Zaniboni, A., Negri, F., Quadri, A., Zorzi, F., Galizia, E., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-303 · Cited by 72
“Background The expanding role of anti-EGFR therapeutic modalities in colorectal cancer along with the growing number of cases potentially requiring such a treatment approach made the need for a correct and reliable identification of responding tumors even more relevant [1-7].”
BackgroundEng, C., Bessudo, A., Hart, L. L., Severtsev, A., Gladkov, O., Müller, L., Kopp, M. V., Vladimirov, V., Langdon, R., Kotiv, B., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30049 · Cited by 72
Élez, E., Argilés, G., & Tabernero, J. M. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0369-x · Cited by 83
Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases
Goodman, B. D., Mannina, E. M., Althouse, S. K., Maluccio, M. A., & Cardenes, H. R. (2015) · Practical Radiation Oncology · doi:10.1016/j.prro.2015.10.011 · Cited by 72
KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab
Stremitzer, S., Stift, J., Gruenberger, B., Tamandl, D., Aschacher, T., Wolf, B., Wrba, F., & Gruenberger, T. (2012) · British journal of surgery · doi:10.1002/bjs.8909 · Cited by 82
More is less—combining targeted therapies in metastatic colorectal cancer
Punt, C. J. A., & Tol, J. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.168 · Cited by 82
Adam, R. A., Haller, D. G., Poston, G. J., Raoul, J., Spano, J., Tabernero, J. M., & Cutsem, E. V. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq043 · Cited by 78
Scartozzi, M., Bearzi, I., Mandolesi, A., Giampieri, R., Faloppi, L., Galizia, G., Loupakis, F., Zaniboni, A., Zorzi, F., Biscotti, T., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.161 · Cited by 73
“We now know that under normal circumstances, EGFR expression is primarily regulated by the abundance of its m-RNA (Scartozzi et al, 2007; Van Cutsem et al, 2009).”
BackgroundMolecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer
Di Fiore, F., Sesboüé, R., Michel, P., Sabourin, J. C., & Frebourg, T. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6606008 · Cited by 71
Therapeutic Targets and Tumor Microenvironment in Colorectal Cancer
Gallo, G., Vescio, G., Paola, G. D., & Sammarco, G. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112295 · Cited by 75
“Aflibercept is a recombinant fusion protein composed of the constant Fc domain of human IgG and the second and third immunoglobulin domains of VEGFR-1 and VEGFR-2, respectively.”
BackgroundMaréchal, R., Schutter, J. D., Nagy, N., Demetter, P., Lemmers, A., Deviere, J. M. E., Salmon, I. J., Tejpar, S., & Laethem, J. V. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-340 · Cited by 82
Self-citationLáng, I., Köhne, C.-H., Folprecht, G., Rougier, P. R., Curran, D., Hitre, E., Sartorius, U., Griebsch, I., & Cutsem, E. V. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.08.023 · Cited by 74
Self-citationNew Strategies for Treatment of KRAS Mutant Metastatic Colorectal Cancer
Prenen, H., Tejpar, S., & Cutsem, E. V. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2029 · Cited by 80
Self-citationImperial, R. J. L., Toor, O. M., Hussain, A., Subramanian, J., & Masood, A. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.016 · Cited by 84
Wong, N. A. C. S., de Castro, D. G., Salto‐Tellez, M., Butler, R., Díaz‐Cano, S. J., Ilyas, M., Newman, W. G., Shaw, E. C., Tanière, P., & Walsh, S. V. (2014) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2014-202467 · Cited by 78
Molecular Testing for Gastrointestinal Cancer
Lee, H. S., Kim, W. H., Kwak, Y., Koh, J., Bae, J. M., Kim, K., Chang, M. S., Han, H. S., Kim, J. M., Kim, H. W., et al. (2017) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2017.01.24 · Cited by 72
Matos, A. I., Carreira, B., Peres, C., Moura, L. I. F., Conniot, J., Fourniols, T., Scomparin, A., Martínez-Barriocanal, Á., Arango, D., Conde, J. P., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.06.017 · Cited by 68
PRMT1 enhances oncogenic arginine methylation of NONO in colorectal cancer
Yin, X.-K., Wang, Y., Wang, F., Feng, W.-X., Bai, S.-M., Zhao, W.-W., Feng, L.-L., Wei, M., Qin, C.-L., Wang, F., et al. (2021) · Oncogene · doi:10.1038/s41388-020-01617-0 · Cited by 73
Nimotuzumab: beyond the EGFR signaling cascade inhibition
Mazorra, Z., Chao, L., Lavastida, A., Sanchez, B., Ramos, M., Iznaga, N., & Crombet, T. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.04.008 · Cited by 77
Guercio, B. J., Zhang, S., Ou, F., Venook, A. P., Niedzwiecki, D., Lenz, H., Innocenti, F., O’Neil, B. H., Shaw, J. E., Polite, B. N., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01019 · Cited by 73
“During enrollment, the trial underwent major design changes in treatment and KRAS inclusion criteria as a result of evolving science.(22-26) Our cohort includes patients who participated throughout the trial history.”
MethodTargeting BRAF and RAS in Colorectal Cancer
Bellio, H., Fumet, J.-D., & Ghiringhelli, F. (2021) · Cancers · doi:10.3390/cancers13092201 · Cited by 75
Lee, Y.-S., Choi, K.-M., Kim, W., Jeon, Y.-S., Lee, Y., Hong, J. T., Yun, Y., & Yoo, H. (2013) · Journal of Natural Products · doi:10.1021/np4005135 · Cited by 74
Role of targeted agents in metastatic colorectal cancer
Prenen, H., Vecchione, L., & Cutsem, E. V. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0281-x · Cited by 76
“Cetuximab and panitumumab, two monoclonal antibodies that, by targeting and binding the extracellular domain of the EGFR inhibit its dimerization and activation, improve the outcome of metastatic CRC (mCRC) patients either as monotherapy or in combination with chemotherapy [8, 13–16].”
BackgroundTakegawa, N., Yonesaka, K., Sakai, K., Ueda, H., Watanabe, S., Nonagase, Y., Okuno, T., Takeda, M., Maenishi, O., Tsurutani, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6498 · Cited by 70
Metadata
- Authors
- Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., Roh, J. K., Folprecht, G., Ruff, P., Stroh, C., Tejpar, S., Schlichting, M., Nippgen, J., & Rougier, P.
- Affiliations
- Klinikum Oldenburg (DE)
- Moscow City Oncology Hospital №62 (RU)
- Petz Aladár Megyei Oktató Kórház (HU)
- National University Hospital (SG)
- Yonsei University (KR)
- University Hospital Carl Gustav Carus (DE)
- University of the Witwatersrand (ZA)
- Merck KGaA, Darmstadt (Germany) (DE)
- Universitair Ziekenhuis Leuven (BE)
- Hôpital Ambroise-Paré (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-04-02
- Volume
- 360
- Issue
- 14
- Pages
- 1408-1417
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2095201384
- Cited by
- 3,877
- References
- 34
- Citations by year
- 2026: 83 · 2025: 87 · 2024: 105 · 2023: 136 · 2022: 169 · 2021: 173 · 2020: 194 · 2019: 199 · 2018: 172 · 2017: 221 · 2016: 275 · 2015: 307 · 2014: 337 · 2013: 328 · 2012: 331
- FWCI
- 179.06
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- cetuximab, FOLFIRI, metastatic colorectal cancer, first-line therapy, KRAS mutation status, epidermal growth factor receptor, progression-free survival, overall survival, treatment response, adverse events, irinotecan, 5-fluorouracil, leucovorin, skin reactions, diarrhea, infusion reactions, anti-EGFR therapy
- MeSH terms
- Cetuximab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Mutation, Neoplasm Metastasis, Genes, ras, Colorectal Neoplasms, Disease Progression, Kaplan-Meier Estimate, Young Adult, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.